PF PRISM CV
Big PharmaPF PRISM CV is a major pharmaceutical company focused on Oncology, Infectious Disease, Dermatology. Key products include XELJANZ.
PF PRISM CV at a Glance
- Strong track record with 80% execution quality across 5 trials
- Fast trial execution (30 months median completion)
PF PRISM CV's Key Drugs
PF PRISM CV's core commercial portfolio centers on XELJANZ, INLYTA, XALKORI, spanning Oncology and Infectious Disease — its most strategically important drugs approved in the last 15 years.
Moderately to severely active rheumatoid arthritis
First-line treatment of advanced renal cell carcinoma in combination with avelumab
Non-Small Cell Lung Cancer
Chronic Myelogenous Leukemia
PF PRISM CV's Recent FDA Approvals
New NDA/BLA approvals for PF PRISM CV over the last two years — novel drugs only, excluding generics and label supplements.
PF PRISM CV's Therapeutic Areas
PF PRISM CV's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Infectious Disease, across 0 biologic and 10 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
PF PRISM CV's Top Competitors
PF PRISM CV's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Johnson & Johnson, and Bristol-Myers Squibb. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
PF PRISM CV Pipeline Snapshot
Active clinical trials for PF PRISM CV across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • XELJANZ leads revenue
- • 4 key drugs tracked
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 0/0 completed
- • Speed: 30 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges